Tecvayli

News

A trial to see if Poolbeg's POLB-001 can prevent cytokine release syndrome in multiple myeloma treated with immunotherapy Tecvayli will start soon.

News

ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.

News

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

J&J says its sales should top $100 billion this year, as it pushes its oncology business towards a target of $50 billion by the end of the decade.

News

Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.